Speaker Details

Jennifer Lin Hsiao, MD, FAAD

Jennifer Lin Hsiao, MD, FAAD

SESSIONS

U018 Innovative and Advanced Management of Biologics and Small Molecule Inhibitors in Hidradenitis Suppurativa and Beyond
Mar 27, 2026 • 3:30 PM - 4:30 PM • Bluebird 3E
S030 A New Paradigm in the Management of the Hidradenitis Suppurativa Disease Spectrum
Mar 28, 2026 • 9:00 AM - 12:00 PM • Mile High 2B
F039 Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach
Mar 28, 2026 • 1:00 PM - 3:00 PM • Four Seasons 4
F058 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
Mar 29, 2026 • 1:00 PM - 3:00 PM • Bluebird 1B

DISCLOSURES

AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);